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ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies and the 
third leading cause of cancer-related deaths worldwide. HCC carries poor prognosis, 
its incidence and mortality increase annually. The most common hypothesis explaining 
the problem is the cell’s high tendency to metastasize and recur, even after surgical 
treatment. Therefore, it is important to find new serological biomarkers to detect 
HCC in early stages. Plasma microRNAs are being actively investigated as minimally-
invasive biomarkers in HCC as well as other human cancers.
This study is aimed to investigate the level of expression of miR-21, miR-29c, and 
miR-155 as novel serological biomarkers for hepatocellular carcinoma.
This study is preliminary quasi experimental study, and further sample collection is still 
underway. This study involved 8 HCC patients and 8 healthy controls. Blood sample 
of HCC patients were obtained from RSUP dr. Sardjito, Yogyakarta, and the patients 
were selected according to specific inclusion and exclusion criteria. The collected 
blood samples were treated as follows: plasma isolation, RNA total isolation, cDNA 
synthesis, quantification by qRT-PCR, data analysis with Biorad CFX ManagerTM 
Softwere to determine Cq, followed by the calculation of expression levels using Livax 
Methods.
The result revealed that miR-21 and miR-155 were upregulated, 1.68 fold and 2.38 
fold respectively, compared to healthy control. Secondly, miR-29c was downregulated 
(3,45 fold) compared to healthy control. 
Based on the result of preliminary study, we concluded that miR-21 acts as oncomiR, 
while miR-29c and miR-155 act as tumor supressor miR in HCC. The three microRNAs 
might be detected in HCC and might be used as minimally-invasive biomarkers in HCC 
detection.
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